Mortality among patients aged 80 years or older was 7.4% vs. 1.4% in those aged 60 to 69 years.
2023
Physicians Discuss Frontline Immunotherapies for Metastatic Melanoma
During a Targeted Oncology™ Case-Based Roundtable™ event, Evan J. Lipson, MD, and participants discussed factors influencing their choice of immunotherapy for a patient with BRAF-negative metastatic melanoma.
Clinical Trial Evaluates Smaller Surgical Margins for Stage 2 Melanoma Patients
Although most primary cutaneous melanomas are treated with surgical excision alone, current international guidelines vary on the optimal size for the surgical margins, which can range from 1 to 3 cm.
Low Risk of Melanoma-Specific Mortality Seen in Patients With MIS
The incidence rate of melanoma in situ (MIS) has sharply risen since 1975.